The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors

Basit Öğe Kaydı
dc.authoridAksoy, Sercan/0000-0003-4984-1049
dc.authoridSahin, Taha Koray/0000-0002-3590-0426
dc.authoridOzbek, Deniz Aral/0000-0002-3256-3284
dc.authoridErul, Enes/0000-0002-2487-2087;
dc.authorwosidAksoy, Sercan/S-2480-2019
dc.authorwosidSahin, Taha Koray/ABH-1748-2020
dc.authorwosidOzbek, Deniz Aral/ABH-1721-2020
dc.authorwosidErul, Enes/AGJ-5340-2022
dc.authorwosidyıldırım, hasan çağrı/HSH-7012-2023
dc.contributor.authorGuven, Deniz Can
dc.contributor.authorOzbek, Deniz Aral
dc.contributor.authorSahin, Taha Koray
dc.contributor.authorKavgaci, Gozde
dc.contributor.authorAksun, Melek Seren
dc.contributor.authorErul, Enes
dc.contributor.authorYildirim, Hasan Cagri
dc.date.accessioned2024-05-19T14:38:49Z
dc.date.available2024-05-19T14:38:49Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractRecent observational studies reported acute kidney injury (AKI) events in over 10% of the patients treated with immune checkpoint inhibitors (ICIs). However, these studies included patients treated in high-resource settings and earlier lines. Therefore, we aimed to assess the AKI rates and predisposing factors in ICI-treated patients from a limited resource setting. We evaluated 252 patients with advanced cancer for this retrospective cohort study. AKI events were defined by Kidney Disease Improving Global Outcomes criteria. The median age was 59 years. The melanoma (18.3%), non-small cell lung cancer (14.7%) and renal cell carcinoma (22.6%) patients comprised over half of the cohort. During the follow-up, 45 patients (17.9%) had at least one AKI episode. In multivariable analyses, patients with chronic kidney disease (CKD) [odds ratio (OR), 3.385; 95% confidence interval (CI), 1.510-7.588; P = 0.003], hypoalbuminemia (OR, 2.848; 95% CI, 1.225-6.621; P = 0.015) or renin-angiotensin-aldosterone system (RAAS) inhibitor use (OR, 2.236; 95% CI, 1.017-4.919; P = 0.045) had increased AKI risk. There was a trend towards increased AKI risk in patients with diabetes (OR, 2.042; 95% CI, 0.923-4.518; P = 0.78) and regular proton pump inhibitors use (OR, 2.024; 95% CI, 0.947-4.327; P = 0.069). In this study, we observed AKI development under ICIs in almost one in five patients with cancer. The increased AKI rates in CKD, hypoalbuminemia or RAAS inhibitor use pointed out a need for better onco-nephrology collaboration and efforts to improve the nutritional status of ICI-treated patients.en_US
dc.identifier.doi10.1097/CAD.0000000000001463
dc.identifier.endpage790en_US
dc.identifier.issn0959-4973
dc.identifier.issn1473-5741
dc.identifier.issue6en_US
dc.identifier.pmid36729111en_US
dc.identifier.scopus2-s2.0-85159738637en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage783en_US
dc.identifier.urihttps://doi.org10.1097/CAD.0000000000001463
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4620
dc.identifier.volume34en_US
dc.identifier.wosWOS:000986236000008en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofAnti-Cancer Drugsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectAcute Kidney Injuryen_US
dc.subjectAdverse Eventen_US
dc.subjectImmunotherapyen_US
dc.subjectImmune Checkpoint Inhibitoren_US
dc.subjectRenalen_US
dc.titleThe incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitorsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu